Mammalian target of rapamycin (mTOR) inhibitors have shown limited therapeutic effectiveness in treating malignant PEComa with TFE3 rearrangement, whereas inhibitors targeting the vascular endothelial growth factor (VEGF)/VEGFR pathway offer a promising alternative therapeutic approach [18]. This evidence concerns the gene KDR and neoplasm with perivascular epithelioid cell differentiation.